Drug–Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model
The Journal of Clinical Pharmacology · 2023
DOI: 10.1002/jcph.2298 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2023. Verfasst von Manting Chiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Myers Squibb, Princeton, NJ, USA. Hauptthemen laut MEDLINE: Ethinyl Estradiol, Models, Biological, Norethindrone, Contraceptives, Oral. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Mavacamten is a potential inducer of cytochrome P450 (CYP) 3A4 and, as such, could reduce the exposure of the active components of oral contraceptives, ethinyl estradiol (EE) and norethindrone (NOR), where CYP3A4 is involved in metabolism. This study assessed if repeat doses of mavacamten led to a drug–drug interaction with EE and/or NOR. This was an open‐label study in healthy women. In Period 1, participants received 35 mcg of EE and 1 mg of NOR. In Period 2, participants received oral loading doses of mavacamten 25 mg on Days 1–2, 15 mg/day on Days 3‒17, and 35 mcg of EE and 1 mg of NOR on Day 15. Plasma concentrations of mavacamten, EE, and NOR were obtained before dosing and up to 72 hours after dosing. For EE only, a physiologically based pharmacokinetic model was used to simulate mavacamten‐mediated CYP3A4 induction with EE for various CYP2C19 phenotypes. In total, 13 women were enrolled (mean age, 38.9 [standard deviation, 9.65] years). After mavacamten administration, modest increases in area under the concentration–time curves were observed for both EE and NOR. The maximum concentrations and half‐lives for EE and NOR were not affected by coadministration with mavacamten. Criteria for bioequivalence were met or nearly met for EE and NOR exposure with geometric mean ratios between 0.8 and 1.25. All adverse events were mild. The physiologically based pharmacokinetic model predicted a less than 15% decrease in EE exposure across CYP2C19 phenotypes. Coadministration of mavacamten at a therapeutically relevant dose with EE and NOR did not decrease the exposure to either EE or NOR to a level that may lead to reduced effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bristol Myers Squibb, Princeton, NJ, USA.
- Daniel Gretler Consulting, San Francisco, CA, USA.
Zitieren
APA
Chiang, M., Sychterz, C., Gaohua, L., Perera, V., Gretler, D. D., Florea, V., & Merali, S. (2023). Drug–Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2298
Vancouver
Chiang M, Sychterz C, Gaohua L, Perera V, Gretler DD, Florea V, et al. Drug–Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model. The Journal of Clinical Pharmacology. 2023. doi:10.1002/jcph.2298
BibTeX
@article{Chiang2023,
author = {Chiang, Manting and Sychterz, Caroline and Gaohua, Lu and Perera, Vidya and Gretler, Daniel D and Florea, Victoria and Merali, Samira},
title = {Drug–Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model},
journal = {The Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1002/jcph.2298}
}
EUVIMED